Abstract 307P
Background
The incident rate of thyroid nodules has risen globally, thus it is critical to identify malignancy among benign lesions. Currently available molecular diagnostics for malignant nodules have not achieved the desired degree of accuracy. We aimed to identify DNA methylation markers to accurately classify benign and malignant nodules, and to develop tools for non-invasive screening of thyroid cancer.
Methods
Marker screening was performed on papillary thyroid cancer (PTC, 37 tissues, 55 plasmas), benign nodules (BTN, 37 tissues, 55 plasmas) and normal samples (20 buffy coats; 123 plasmas) by MONOD+ assay. We identified differential markers by Wilcox rank sum test using Benjamini-Hochberg procedure to control false discovery rate. Predication models were built using machine-learning algorithms including random forest and support vector machine. They were validated using public DNA methylation data of thyroid tissues. Candidate markers were developed into a targeted sequencing panel and were validated on plasma DNA samples (115 PTC, 102 BTN). Best-performing markers were developed into an improved panel to classify additional plasma DNA samples of malignant or benign thyroid nodules.
Results
From the MONOD+ data we identified over 1000 DNA methylation markers significantly differential between malignant and benign nodules. We built a classification model by random forest method, which classified DNA methylation profiles of thyroid nodules at a sensitivity of 90.5% and a specificity of 91.9% (95% CI, 0.91-1.0). We produced a targeted sequencing panel using those markers and sequenced plasma DNA of PTC and benign nodules. Two thirds of them were used as a training cohort to build a prediction model, which classified the remaining samples at an accuracy of 72%. We selected the best-performing markers to build an advanced version of panel, which classified additional over 500 plasma DNA samples of thyroid nodules with increased sequencing depth to improve the accuracy and consistency in classification.
Conclusions
Our study demonstrates that DNA methylation markers can robustly differentiate thyroid nodules based on their malignancy. They are thus promising candidates to develop non-invasive diagnostics for thyroid cancer screening.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The First Affiliated Hospital, Sun Yat-sen University.
Funding
The First Affiliated Hospital, Sun Yat-sen University.
Disclosure
Z. Su, Q. He: Shareholder/Stockholder/Stock options, Full/Part-time employment: Singlera Genomics. L. Cheng: Full/Part-time employment: Singlera Genomics. R. Liu: Leadership role, Shareholder/Stockholder/Stock options, Full/Part-time employment: Singlera Genomics. All other authors have declared no conflicts of interest.
Resources from the same session
163P - Gastrointestinal stromal tumours (GIST) in adolescents and young adults (AYA) in an Asian institution from 2002 to 2018
Presenter: Evelyn Yi Ting Wong
Session: e-Poster Display Session
164P - The impact of sarcopenia on chemotherapy toxicity and survival rate among hepatocellular carcinoma patients who underwent chemotherapy: A systematic review and meta-analysis
Presenter: Elizabeth Marcella
Session: e-Poster Display Session
165P - Prognostic factors in sorafenib-treated hepatocellular carcinoma: Multicentre analysis of a European population sample
Presenter: João Gramaça
Session: e-Poster Display Session
166P - Differences and similarities in presentation and management patterns in patients with hepatocellular carcinoma (HCC) across Hong Kong, Singapore and Thailand
Presenter: Pierce Chow
Session: e-Poster Display Session
167P - Epidemiology of hepatocellular carcinoma (HCC) in tertiary level hospitals in Bangladesh
Presenter: Abdullah Al Mamun Khan
Session: e-Poster Display Session
168P - Response assessments in hepatocellular carcinoma: What are the best criteria to utilize? mRECIST or RECIST 1.1? A retrospective meta-analysis of multiple phase III trials
Presenter: Oliver Bohnsack
Session: e-Poster Display Session
169P - IMbrave150: Management of adverse events of special interest (AESIs) for atezolizumab (atezo) and bevacizumab (bev) in unresectable HCC
Presenter: Masatoshi Kudo
Session: e-Poster Display Session
170P - Sintilimab plus anlotinib as first-line therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC)
Presenter: Xiaofeng Chen
Session: e-Poster Display Session
171P - Transarterial chemoembolization (TACE) plus lenvatinib versus TACE plus sorafenib for hepatocellular carcinoma (HCC) with portal vein tumour thrombus (PVTT): A prospective randomized study
Presenter: Xiaoyan Ding
Session: e-Poster Display Session
172P - Triple combination therapy of lenvatinib, toripalimab, and hepatic arterial infusion chemotherapy versus lenvatinib for advanced hepatocellular carcinoma
Presenter: Zhi-Cheng Lai
Session: e-Poster Display Session